Selexipag

Global Branded PAH Therapeutics Market Report 2023: Analysis by Drug Class, RoA, Distribution - Market Insights and Forecasts 2019-2029 - ResearchAndMarkets.com

Retrieved on: 
Friday, December 15, 2023
Health, Pharmaceutical, Acquisition, Research, Global Brands Group, Prevalence, Market, Therapy, Incidence, Pulmonary hypertension, Pulmonary Vascular Research Institute, Disease, Patient, Route of administration, USD, Selexipag, Macitentan, Prescription, Pharmacy, Administration, Diagnosis, PAH, Quality of life, Endothelin receptor antagonist, Research report, Pharmaceutical industry

The "Global Branded PAH Therapeutics Market (2023 Edition) - Analysis By Drug Class, Route of Administration, Distribution Channel, By Region, By Country: Market Insights and Forecast (2019-2029)" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Branded PAH Therapeutics Market (2023 Edition) - Analysis By Drug Class, Route of Administration, Distribution Channel, By Region, By Country: Market Insights and Forecast (2019-2029)" report has been added to ResearchAndMarkets.com's offering.
  • The Global Branded PAH Therapeutics Market is expected to generate USD 9868.66 million by the end of 2029, up from USD 6671.17 million in 2022.
  • During the forecast period, 2024-2029, Global Branded PAH Therapeutics is expected to expand at a CAGR of 5.89%.
  • Additionally, the research report presents data including market size, yearly growth & potential analysis, the competitive study of market players, investment opportunities and demand forecast.

Global Pulmonary Arterial Hypertension Market and Forecast Analysis Report 2021-2027 - ResearchAndMarkets.com

Retrieved on: 
Tuesday, June 8, 2021
Health, Cardiology, Hypertension, Anatomy, Chemistry, Cardiovascular system, Pulmonary hypertension, Chronic thromboembolic pulmonary hypertension, Selexipag, Pulmonary artery, PAH, Actelion

The "Pulmonary Arterial Hypertension Market and Forecast Analysis to 2025" drug pipelines has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Pulmonary Arterial Hypertension Market and Forecast Analysis to 2025" drug pipelines has been added to ResearchAndMarkets.com's offering.
  • The report estimates that in 2018, there were approximately 218,500 prevalent cases of pulmonary arterial hypertension (PAH) in individuals of all ages worldwide, and forecasts that number to increase to 241,800 prevalent cases by 2027.
  • Additionally, this will markedly expand the prostacyclin class's potential by encouraging first-line uptake alongside Opsumit, which is a market leader.
  • Market leaders Opsumit and Uptravi are being investigated in clinical trials to potentially support label expansions to chronic thromboembolic pulmonary hypertension (CTEPH).

New Real-World Observational Analysis of UPTRAVI® (selexipag) Underscores the Importance of Risk Assessment for Treating Pulmonary Arterial Hypertension (PAH) Patients

Retrieved on: 
Tuesday, April 6, 2021
Chemistry, Chemical compounds, Organic compounds, Carboxylic acids, Hypertension, Prostaglandins, Secondary alcohols, Sulfonamides, Pulmonary hypertension, Selexipag, Prostacyclin, Riociguat

In the pivotal GRIPHON trial, UPTRAVI was proven to reduce the risk of disease progression by 40%.

Key Points: 
  • In the pivotal GRIPHON trial, UPTRAVI was proven to reduce the risk of disease progression by 40%.
  • SPHERE enrolled patients who were either newly initiated on UPTRAVI (60 days before enrollment) or previously received UPTRAVI with documentation of dose titration at study enrollment.
  • The efficacy of UPTRAVI in PAH was established in GRIPHON (Prostacyclin [PGI2] Receptor agonist In Pulmonary arterial HypertensiON), the largest randomized, controlled trial ever conducted in PAH patients.
  • Hyperthyroidism was observed in 1% (n=8) of patients on UPTRAVI and in none of the patients on placebo.

Results from Expert Delphi Consensus Survey on Treatment of Pulmonary Arterial Hypertension (PAH) with Oral Prostacyclin Pathway Agents (PPAs) Published in CHEST Journal

Retrieved on: 
Friday, April 3, 2020
Chemistry, Functional groups, Organic chemistry, Healthcare quality, Systems thinking, Delphi method, Forecasting, Prediction, Technology forecasting, Medical guideline, Prostacyclin, Selexipag

The consensus opinions were formed utilizing the RAND/University of California Los Angeles Appropriateness Method, which incorporates the Delphi method and nominal group technique.

Key Points: 
  • The consensus opinions were formed utilizing the RAND/University of California Los Angeles Appropriateness Method, which incorporates the Delphi method and nominal group technique.
  • The Prostacyclin International Expert Panel opinion survey statements are not intended to be formal treatment guidelines or recommendations, and survey results presented here must be validated with rigorous prospective studies.
  • The Prostacyclin International Expert Panel opinion survey statements cannot replace assessment and/or clinical decision-making by a qualified healthcare practitioner for an individual patient.
  • UPTRAVI is the only oral treatment that works on the prostacyclin pathway with evidence of long-term outcomes.

Orenitram (treprostinil; United Therapeutics) Market Overview - Newer Brand Uptravi (selexipag; Johnson & Johnson/Nippon Shinyaku) Poses Tough Competition in the Oral Prostacyclin Class

Retrieved on: 
Wednesday, June 26, 2019
Chemistry, Chemical compounds, Organic compounds, Prostaglandins, Alcohols, Treprostinil, Carboxylic acids, Prostacyclin, Selexipag, United Therapeutics, Johnson & Johnson, Repros Therapeutics

Orenitram (treprostinil; United Therapeutics) is a novel formulation of the prostacyclin analog treprostinil, formulated using Supernus Pharmaceuticals' drug delivery technology, allowing for twice-daily oral dosing.

Key Points: 
  • Orenitram (treprostinil; United Therapeutics) is a novel formulation of the prostacyclin analog treprostinil, formulated using Supernus Pharmaceuticals' drug delivery technology, allowing for twice-daily oral dosing.
  • Moreover, newer brand Uptravi (selexipag; Johnson & Johnson/Nippon Shinyaku) poses tough competition in the oral prostacyclin class.
  • While United Therapeutics is investing in further developing Orenitram, the author ultimately does not foresee Orenitram outcompeting Uptravi as the former's clinical profile is unconvincing.
  • Nevertheless, Orenitram is still expected to indirectly benefit from the TRITON trial investigating the value of triple combination therapy with an oral prostacyclin.

Uptravi (selexipag; Johnson & Johnson/Nippon Shinyaku) Drug Overview 2018: A First-in-Class Oral Selective Non-Prostanoid Prostaglandin I2 (PGI2) Receptor Agonist

Retrieved on: 
Wednesday, June 26, 2019
Chemistry, Chemical compounds, Amides, Prostaglandins, Acetamides, Ethers, Pyrazines, Selexipag, Sulfonamides, Macitentan, Endothelin receptor antagonist, Prostanoid

Uptravi (selexipag; Johnson & Johnson/Nippon Shinyaku) is a first-in-class oral selective non-prostanoid prostaglandin I2 (PGI2) receptor agonist.

Key Points: 
  • Uptravi (selexipag; Johnson & Johnson/Nippon Shinyaku) is a first-in-class oral selective non-prostanoid prostaglandin I2 (PGI2) receptor agonist.
  • The drug and its active metabolite, ACT-333679, have a similar mode of action to the prostacyclin analogs, but with greater selectivity for the PGI2 receptor.
  • Uptravi (selexipag; Johnson & Johnson/Nippon Shinyaku) is positioned to become the second highest-selling drug behind Opsumit (macitentan; Johnson & Johnson/Nippon Shinyaku) in the forecast period, with strong peak sales of $1.5bn across the forecast markets.
  • Furthermore, Uptravi is being investigated in a triple combination regimen with a phosphodiesterase 5 (PDE5) inhibitor and Johnson & Johnson's endothelin receptor antagonist (ERA) Opsumit.

Orenitram (treprostinil; United Therapeutics) Drug Profile 2016-2025 - ResearchAndMarkets.com

Retrieved on: 
Wednesday, June 26, 2019
Biotechnology, Pharmaceutical, Health, Chemical compounds, Chemistry, Organic compounds, Prostaglandins, Alcohols, Treprostinil, Carboxylic acids, Prostacyclin, United Therapeutics, Selexipag

Orenitram (treprostinil; United Therapeutics) is a novel formulation of the prostacyclin analog treprostinil, formulated using Supernus Pharmaceuticals' drug delivery technology, allowing for twice-daily oral dosing.

Key Points: 
  • Orenitram (treprostinil; United Therapeutics) is a novel formulation of the prostacyclin analog treprostinil, formulated using Supernus Pharmaceuticals' drug delivery technology, allowing for twice-daily oral dosing.
  • Orenitram represents the continuation of United Therapeutics' PH portfolio, led by intravenous Remodulin.
  • While United Therapeutics is investing in further developing Orenitram, the author ultimately does not foresee Orenitram outcompeting Uptravi as the former's clinical profile is unconvincing.
  • Nevertheless, Orenitram is still expected to indirectly benefit from the TRITON trial investigating the value of triple combination therapy with an oral prostacyclin

Uptravi (selexipag; Johnson & Johnson/Nippon Shinyaku) Drug Overview & Product Profiles 2016-2025 - ResearchAndMarkets.com

Retrieved on: 
Wednesday, June 26, 2019
Pharmaceutical, Health, Cardiology, Chemistry, Chemical compounds, Amides, Prostaglandins, Acetamides, Ethers, Pyrazines, Selexipag, Sulfonamides, Macitentan, Endothelin receptor antagonist, Prostanoid

Uptravi (selexipag; Johnson & Johnson/Nippon Shinyaku) is a first-in-class oral selective non-prostanoid prostaglandin I2 (PGI2) receptor agonist.

Key Points: 
  • Uptravi (selexipag; Johnson & Johnson/Nippon Shinyaku) is a first-in-class oral selective non-prostanoid prostaglandin I2 (PGI2) receptor agonist.
  • The drug and its active metabolite, ACT-333679, have a similar mode of action to the prostacyclin analogs, but with greater selectivity for the PGI2 receptor.
  • Uptravi (selexipag; Johnson & Johnson/Nippon Shinyaku) is positioned to become the second highest-selling drug behind Opsumit (macitentan; Johnson & Johnson/Nippon Shinyaku) in the forecast period, with strong peak sales of $1.5bn across the forecast markets.
  • Furthermore, Uptravi is being investigated in a triple combination regimen with a phosphodiesterase 5 (PDE5) inhibitor and Johnson & Johnson's endothelin receptor antagonist (ERA) Opsumit.